<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>BELEODAQ (belinostat) for injection - for Healthcare Professionals (HCPs)</title>
    <meta name="description" content="In the next round against relapsed or refractory PTCL, fight on with BELEODAQ. It is an HDAC inhibitor available for relapsed/refractory PTCL.">
    <!-- Favicon -->
    <link rel="icon" href="https://beleodaq.com/hcp/wp-content/uploads/2019/05/cropped-favicon-Beleodaq-32x32.png" sizes="32x32">
    <!-- Google fonts -->
    <link rel="preconnect" href="https://fonts.gstatic.com">
    <link href="https://fonts.googleapis.com/css2?family=Open+Sans:wght@300;400;600;700;800&family=Raleway:wght@700&display=swap" rel="stylesheet">
    <!-- CSS Reset -->
    <link rel="stylesheet" href="css/reset.css">
    <!-- Stylesheet -->
    <link rel="stylesheet" href="css/dosing.css">
</head>
<body>
    <!-- Header -->
    <header class="header">
        <!-- Indications and Usage -->
        <div class="indications">
            <h5 class="indications__title">Indications and Usage</h5>
            <p class="indications__body copyright">BELEODAQ is a histone deacetylase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon veriﬁcation and description of clinical beneﬁt in the conﬁrmatory trial.</p>
        </div>
        <!-- Navigation -->
        <nav class="nav">
            <!-- Logo -->
            <a class="nav__logo" href="index.html">
                <img src="https://beleodaq.com/hcp/wp-content/uploads/2019/04/logonew.png" alt="BELEODAQ® (belinostat) for injection: For injection in the treatment of relapsed or refractory PTCL">
            </a>
            <!-- Header Buttons -->
            <div class="nav__buttons">
                <!-- Site Buttons (redirecting to other parts of site) -->
                <ul class="site-buttons">
                    <li>
                        <a class="site-buttons__button p" href="#">
                            Important Safety Information
                        </a>
                    </li>
                    <li>
                        <a class="site-buttons__button p"
                        href="#">
                           Prescribing Information
                        </a>
                    </li>
                    <li>
                        <a class="site-buttons__button button--orange p" href="#">
                           Patient Site
                        </a>
                    </li>
                </ul>
                <!-- Nav Links and Dropdown Menus -->
                <ul class="navlinks">
                    <li>
                        <a class="navlinks__link p" href="ptcl.html">PTCL <br>Overview</a>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="about.html">About <br>Beleodaq</a>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="about.html">BELIEF <br>Trial</a>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="efficacy.html"><br>Efficacy</a>
                        <ul class="dropdown dropdown--hidden">
                            <li>
                                <a href="" class="dropdown__item p">
                                    Study design
                                </a>
                            </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Baseline Characteristics
                                </a>
                            </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Response Rate
                                </a>
                             </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Duration of Response
                                </a>
                            </li>
                        </ul>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="safety.html">Safety & Tolerability</a>
                        <ul class="dropdown dropdown--hidden">
                            <li>
                                <a href="" class="dropdown__item p">
                                    Adverse Reactions
                                </a>
                            </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Tolerability
                                </a>
                            </li>
                        </ul>
                    </li>
                    <li class="active">
                        <a class="navlinks__link--active p" href="dosing.html">Dosing & Administration</a>
                        <ul class="dropdown dropdown--hidden">
                            <li>
                                <a href="" class="dropdown__item p">
                                    Dosing Schedule
                                </a>
                            </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Dose Modifications
                                </a>
                            </li>
                        </ul>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="#">Access & Resources</a>
                        <ul class="dropdown dropdown--hidden">
                            <li>
                                <a href="" class="dropdown__item p">
                                    STAR
                                </a>
                            </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Resources
                                </a>
                            </li>
                        </ul>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="#">Contact <br>Us</a>
                    </li>
                </ul>
            </div>
        </nav>
    </header>
    <!-- Main -->
    <main>
        <h2 class="primary">Just a Short, 30-Minute Intravenous Infusion</h2>
       
        <h3 class="secondary-variant">No recommended pretreatment is required<sup>1</sup></h3>

        <div class="timeline">
            <div class="timeline__item">
                <h4 class="primary semibold">Dosage</h4>
                <img src="assets/svg/dosing/iv.svg" alt="IV Bag" />
                <h4 class="light">The <span class="primary semibold">recommended dosage of BELEODAQ</span> is 1000 mg/m2</h4>
            </div>
            <div class="timeline__item">
                <img src="assets/svg/dosing/arrow.svg" alt="Next Arrow" />
            </div>
            <div class="timeline__item">
                <h4 class="primary semibold">Infusing Time</h4>
                <img src="assets/svg/dosing/watch.svg" alt="stop watch" />
                <h4 class="light">Short, 
                    infusion <span class="primary semibold">30-minute</span></h4>
            </div>
            <div class="timeline__item">
                <img src="assets/svg/dosing/arrow.svg" alt="Next Arrow" />
            </div>
            <div class="timeline__item">
                <h4 class="primary semibold">Dosing Schedule</h4>
                <img src="assets/svg/dosing/calendar.svg" alt="calendar" />
                <h4 class="light"><span class="primary semibold">5 days</span> on,<br>
                    <span class="primary semibold">16 days</span> off<sup>*</sup></h4>
            </div>
        </div>

        <p class="light">*Repeat every 21 days until disease progression or unacceptable toxicity.<sup>1</sup>
        </p>

        <h2 class="primary">
            Modify BELEODAQ Treatment by Adjusting Dosage as Needed<sup>1</sup>
        </h2>
        <h3 class="secondary-variant">Modifying the dosage may allow for the possibility of continued treatment in some patients<sup>1</sup></h3>
        <div class="toxicity">
            <div class="toxicity__item">
                <h3 class="secondary-variant">Dosage modifications for hematologic toxicities<sup>1</sup></h3>
                <ul>
                    <li>
                        <h4 class="light">
                        Base dosage adjustments for thrombocytopenia and neutropenia on the nadir (lowest value) for platelet and absolute neutrophil count (ANC) in the preceding cycle of therapy
                    </h4></li>
                    <li>
                        <h4 class="light">
                        ANC should be ≥100,000/μL, and the platelet count should be ≥50,000/μL prior to the start of each cycle and prior to resuming treatment following discontinuation because of toxicity
                        <ul>
                            <li>Resume subsequent treatment with BELEODAQ according to the guidelines described in the table to the right</li>
                            <li>Discontinue BELEODAQ in patients who have recurrent ANC nadirs &lt;50,000/μL and/or recurrent platelet count nadirs &lt;25,000/μL after 2 dosage reductions</li>
                        </ul>
                    </h4></li>
                </ul>
                <h3 class="secondary-variant">Preparation and administration precautions<sup>1</sup></h3>
                <ul>
                    <li>
                        <h4 class="light">
                        As with other potentially cytotoxic anticancer agents, exercise care in the handling and preparation of solutions prepared with BELEODAQ</h4></li>
                </ul>
            </div>
            <div class="toxicity__item">
                <h3 class="secondary-variant">Toxicity and dosage modification<sup>1</sup></h3>
                <div class="box darkest">
                    <div class="box__header">
                    <h4><span class="semibold">Platelet count</span> ≥ 25,000/μL and<br>
                        <span class="semibold">nadir ANC</span> ≥ 50,000/μL</h4>
                    </div>
                    <div class="box__content">
                        <h5>NO CHANGE</h5>
                    </div>
                </div>
                <div class="box darker">
                    <div class="box__header">
                    <h4><span class="semibold">Nadir ANC</span> &lt; 50,000/μL<br>
                        (any platelet count)</h4>
                    </div>
                    <div class="box__content">
                        <h5>DECREASE DOSAGE BY
                            <span class="jumbo">25%</span>
                            <span class="light">(750 mg/m2)</span></h5>
                    </div>
                </div>
                <div class="box">
                    <div class="box__header">
                    <h4><span class="semibold">Platelet count</span> &lt; 25,000/μL<br>
                        (any nadir ANC)</h4>
                    </div>
                    <div class="box__content">
                        <h5>DECREASE DOSAGE BY
                            <span class="jumbo">25%</span>
                            <span class="light">(750 mg/m2)</span></h5>
                    </div>
                </div>
            </div>
        </div>

        <div class="modifications">
            <h4 class="light">
                Toxicities must be NCI-CTCAE grade 2 or less prior to retreatment
            </h4>
            <div class="mod-item">
                <h4 class="secondary-variant">
                    Dosage modifications for nonhematologic toxicities<sup>1</sup>
                </h4>
                <div class="boxes">
                    <div class="box">
                        <div class="box__header">
                            <h4 class="light">Any CTCAE 
                                grade 3 or 4 AE<sup>*</sup></h4>
                        </div>
                        <div class="box__content">
                            <h5>DECREASE DOSAGE BY
                                <span class="jumbo">25%</span>
                                <span class="light">(750 mg/m2)</span></h5>
                        </div>
                    </div>
                    <div class="box">
                        <div class="box__header">
                            <h4 class="light">Recurrence of CTCAE 
                                grade 3 or 4 AE 
                                after 2 dosage reductions </h4>
                        </div>
                        <div class="box__content">
                            <h5>DISCONTINUE
                                <span class="jumbo">BELEODAQ</span>
                                </h5>
                        </div>
                    </div>
                </div>
                <p class="light"><sup>*</sup>For nausea, vomiting, and diarrhea, only dose modify if the duration is >7 days with supportive management.1</p>
            </div>
        </div>

        <div class="bounding_box">
            <div class="bb_item">
                <h4 class="primary">Dosage modifications for patients with reduced UGT1A1 activity<sup>1</sup>
                </h4>
                <div class="item__content">
                    <img src="assets/svg/dosing/down-iv.svg" alt="Down Arrow with IV Bag" />
                    <h4 class="light">Reduce the starting dose of BELEODAQ to <span class="primary semibold">750 mg/m2</span> in patients known to be homozygous for the UGT1A1*28 allele</h4>
                </div>
            </div>
            <div class="bb_item">
                <h4 class="secondary-variant">
                    Use in patients with renal impairment<sup>1</sup>
                </h4>
                <div class="item__content">
                    <img src="assets/svg/dosing/kidney.svg" alt="Kidney Illustration" />
                    <h4 class="light">BELEODAQ exposure <span class="secondary-variant semibold">is not altered in patients</span> with creatinine clearance (CrCl) >39 mL/min<br>
                        There are insufficient data to recommend a dose of BELEODAQ in patients with CrCl ≤39 mL/min
                     </h4>
                </div>
            </div>
        </div>
        <h4 class="secondary">Monitor complete blood counts at baseline and weekly<sup>1</sup><br>
            Perform serum chemistry tests, including renal and hepatic functions, prior to the start of the first dose of each cycle
            <sup>1</sup></h4>

        <div class="button-group">
            <a href="safety.html" class="button secondary">&larr; Safety & Tolerability</a>
            <a href="dosing2.html" class="button">Next &rarr;</a>
        </div>
    </main>
    <!-- ISI -->
    <footer>
        <section class="isi">
            <div>
                <h5 class="isi__header">Select Important Safety Information</h5>
                <p class="isi__body copyright"><span class="isi__body--bold ">Warnings and Precautions</span>
                    BELEODAQ can cause thrombocytopenia, leukopenia (neutropenia and lymphopenia), and/or anemia; monitor blood counts weekly during treatment, and modify dosage as necessary.</p>
            </div>
            <a class="isi__button p" href="#">
                See More <span>&uarr;</span>
            </a>
        </section>
    </footer>
    <!-- Vanilla JS -->
    <script src="js/app.js"></script>
</body>
</html>